The role of BRAF V600 mutation in melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-12

AUTHORS

Paolo A Ascierto, John M Kirkwood, Jean-Jacques Grob, Ester Simeone, Antonio M Grimaldi, Michele Maio, Giuseppe Palmieri, Alessandro Testori, Francesco M Marincola, Nicola Mozzillo

ABSTRACT

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors. More... »

PAGES

85

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1479-5876-10-85

DOI

http://dx.doi.org/10.1186/1479-5876-10-85

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050474099

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22554099


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Melanoma, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, Naples, Italy", 
            "Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori \u201cFondazione G. Pascale\u201d, Via Mariano Semmola, 80131, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ascierto", 
        "givenName": "Paolo A", 
        "id": "sg:person.01212502023.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.478063.e", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirkwood", 
        "givenName": "John M", 
        "id": "sg:person.01274445211.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274445211.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Hopital de la Timone, and Aix-Marseille Univ, 264 Rue St Pierre, 13885, Marseille CEDEX 05, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grob", 
        "givenName": "Jean-Jacques", 
        "id": "sg:person.011671114717.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011671114717.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Melanoma, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Simeone", 
        "givenName": "Ester", 
        "id": "sg:person.01127536021.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127536021.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Melanoma, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grimaldi", 
        "givenName": "Antonio M", 
        "id": "sg:person.0762462504.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762462504.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Medical Oncology and Immunotherapy, Department. of Oncology, University Hospital of of Siena, Istituto Toscano Tumori, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maio", 
        "givenName": "Michele", 
        "id": "sg:person.01061427172.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Research Council", 
          "id": "https://www.grid.ac/institutes/grid.5326.2", 
          "name": [
            "Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmieri", 
        "givenName": "Giuseppe", 
        "id": "sg:person.0762206722.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762206722.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Institute of Oncology", 
          "id": "https://www.grid.ac/institutes/grid.15667.33", 
          "name": [
            "Melanoma and muscle-cutaneous sarcomas Division, Istituto Europeo di Oncologia, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Testori", 
        "givenName": "Alessandro", 
        "id": "sg:person.01021072757.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021072757.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute of Arthritis and Musculoskeletal and Skin Diseases", 
          "id": "https://www.grid.ac/institutes/grid.420086.8", 
          "name": [
            "Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marincola", 
        "givenName": "Francesco M", 
        "id": "sg:person.014223631617.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014223631617.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Melanoma, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mozzillo", 
        "givenName": "Nicola", 
        "id": "sg:person.0752035543.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752035543.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2004.12.149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001105110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.11.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006637390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006916541", 
          "https://doi.org/10.1038/nature08902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006916541", 
          "https://doi.org/10.1038/nature08902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa050092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007050226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa050092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007050226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009288742", 
          "https://doi.org/10.1038/nature08833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009288742", 
          "https://doi.org/10.1038/nature08833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-8-67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009398527", 
          "https://doi.org/10.1186/1479-5876-8-67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.26.6.2262-2272.2006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009784412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011492298", 
          "https://doi.org/10.1038/nature08314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011492298", 
          "https://doi.org/10.1038/nature08314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1002011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012824919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.38.2895", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014032151"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-1443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014291431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1755-148x.2010.00685.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017083437"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.nbt.2012.02.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018116551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/carcin/bgp337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018188968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/carcin/bgp337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018188968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0900780106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018281397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/0471142905.hg1011s57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021035685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2011.160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025711571", 
          "https://doi.org/10.1038/onc.2011.160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.32.4327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027360666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2009.12.040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028106155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.06.052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032185335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature09454", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032620847", 
          "https://doi.org/10.1038/nature09454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature09454", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032620847", 
          "https://doi.org/10.1038/nature09454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.7636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034168619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1104621", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036355137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.00569-09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036424072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molcel.2005.10.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037007117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2011.69", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041614560", 
          "https://doi.org/10.1038/nrclinonc.2011.69"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041864150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-011-0933-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042903875", 
          "https://doi.org/10.1007/s00401-011-0933-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-011-0887-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045069601", 
          "https://doi.org/10.1007/s00401-011-0887-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-1683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047572422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.15.11.6430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050578408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050758604", 
          "https://doi.org/10.1038/nrm1498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050758604", 
          "https://doi.org/10.1038/nrm1498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051449373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074805946", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081992405", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.8503", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083944529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.8502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083948941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.8508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083948947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.8519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083948957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.8548", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083948984"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-na\u00efve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1186/1479-5876-10-85", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2440219", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4055141", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "The role of BRAF V600 mutation in melanoma", 
    "pagination": "85", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f07112b630ccbc8849e70d61f30549f232a39d0f39bea2a6d188eeb81cd943d6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22554099"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101190741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1479-5876-10-85"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050474099"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1479-5876-10-85", 
      "https://app.dimensions.ai/details/publication/pub.1050474099"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1479-5876-10-85"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-85'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-85'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-85'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-10-85'


 

This table displays all metadata directly associated to this object as RDF triples.

329 TRIPLES      21 PREDICATES      80 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1479-5876-10-85 schema:about N188b44022c074827a29c04c42bc65abb
2 N21debfa660fb457288844be2a918f749
3 N3b4af02db704438e93e102d7a840810d
4 N50e3c1998503444f8ef6f0e5ce5ee94c
5 N57da5c63e254435380412475edb24103
6 N5f7f9abb5f554ac59205f3cf6a1630ec
7 N77bc44fcf15745b3b8281eaf9441d65a
8 Nd4fc24a386004ebaa52690c0ed277021
9 Ne4996f74913141e9b3331c9a90faa75a
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author Nc8af633f52cd4a3ca7448b1697ab0442
13 schema:citation sg:pub.10.1007/s00401-011-0887-y
14 sg:pub.10.1007/s00401-011-0933-9
15 sg:pub.10.1038/nature00766
16 sg:pub.10.1038/nature08314
17 sg:pub.10.1038/nature08833
18 sg:pub.10.1038/nature08902
19 sg:pub.10.1038/nature09454
20 sg:pub.10.1038/nrclinonc.2011.69
21 sg:pub.10.1038/nrm1498
22 sg:pub.10.1038/onc.2011.160
23 sg:pub.10.1186/1479-5876-8-67
24 https://app.dimensions.ai/details/publication/pub.1074805946
25 https://app.dimensions.ai/details/publication/pub.1081992405
26 https://doi.org/10.1002/0471142905.hg1011s57
27 https://doi.org/10.1016/j.ccr.2010.11.023
28 https://doi.org/10.1016/j.cell.2009.12.040
29 https://doi.org/10.1016/j.ejca.2011.06.052
30 https://doi.org/10.1016/j.molcel.2005.10.022
31 https://doi.org/10.1016/j.nbt.2012.02.002
32 https://doi.org/10.1056/nejmoa050092
33 https://doi.org/10.1056/nejmoa1002011
34 https://doi.org/10.1056/nejmoa1003466
35 https://doi.org/10.1056/nejmoa1103782
36 https://doi.org/10.1056/nejmoa1104621
37 https://doi.org/10.1056/nejmoa1112302
38 https://doi.org/10.1073/pnas.0900780106
39 https://doi.org/10.1093/carcin/bgp337
40 https://doi.org/10.1111/j.1755-148x.2010.00685.x
41 https://doi.org/10.1128/mcb.00569-09
42 https://doi.org/10.1128/mcb.15.11.6430
43 https://doi.org/10.1128/mcb.26.6.2262-2272.2006
44 https://doi.org/10.1158/0008-5472.can-04-1443
45 https://doi.org/10.1158/0008-5472.can-05-1683
46 https://doi.org/10.1200/jco.2004.12.149
47 https://doi.org/10.1200/jco.2007.15.7636
48 https://doi.org/10.1200/jco.2010.28.15_suppl.8503
49 https://doi.org/10.1200/jco.2010.32.4327
50 https://doi.org/10.1200/jco.2011.29.15_suppl.8502
51 https://doi.org/10.1200/jco.2011.29.15_suppl.8508
52 https://doi.org/10.1200/jco.2011.29.15_suppl.8519
53 https://doi.org/10.1200/jco.2011.29.15_suppl.8548
54 https://doi.org/10.1200/jco.2011.38.2895
55 schema:datePublished 2012-12
56 schema:datePublishedReg 2012-12-01
57 schema:description BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.
58 schema:genre non_research_article
59 schema:inLanguage en
60 schema:isAccessibleForFree true
61 schema:isPartOf N224a6e1903194ca1b8dde6fef7adc8da
62 Nd1e590f202ea4057bb2e55c762081712
63 sg:journal.1032886
64 schema:name The role of BRAF V600 mutation in melanoma
65 schema:pagination 85
66 schema:productId N0a723b9339334663ae42a742f48e9782
67 N7df099595dfc4fd29c8b106b1dddd524
68 N872955d698244b039a55cbaf49c2cdb7
69 N9bced16c05e8420c8d2ce9f7d065c3a5
70 Nb1c5174e4eb64e258868e087b8f79f70
71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050474099
72 https://doi.org/10.1186/1479-5876-10-85
73 schema:sdDatePublished 2019-04-10T16:43
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N8cda85457140462780bbbc91054f5709
76 schema:url http://link.springer.com/10.1186%2F1479-5876-10-85
77 sgo:license sg:explorer/license/
78 sgo:sdDataset articles
79 rdf:type schema:ScholarlyArticle
80 N0a723b9339334663ae42a742f48e9782 schema:name pubmed_id
81 schema:value 22554099
82 rdf:type schema:PropertyValue
83 N12e88b8946d94a39a11976d345a9a412 rdf:first sg:person.01127536021.40
84 rdf:rest Nf80340e4846348cfbef693e0281b5e6a
85 N188b44022c074827a29c04c42bc65abb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Clinical Trials as Topic
87 rdf:type schema:DefinedTerm
88 N18ea12d2af514bc9a61a58d48aeafa7b schema:name Department of Melanoma, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
89 rdf:type schema:Organization
90 N21debfa660fb457288844be2a918f749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Proto-Oncogene Proteins B-raf
92 rdf:type schema:DefinedTerm
93 N224a6e1903194ca1b8dde6fef7adc8da schema:issueNumber 1
94 rdf:type schema:PublicationIssue
95 N2a483edf3c8149118e3a725429c2e0a5 rdf:first sg:person.011671114717.29
96 rdf:rest N12e88b8946d94a39a11976d345a9a412
97 N2fd7156708124e188fa457d461c36f1e rdf:first sg:person.014223631617.46
98 rdf:rest N4aa3b414bf98447c8878259a1fe53467
99 N3b4af02db704438e93e102d7a840810d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Drug Resistance, Neoplasm
101 rdf:type schema:DefinedTerm
102 N4aa3b414bf98447c8878259a1fe53467 rdf:first sg:person.0752035543.31
103 rdf:rest rdf:nil
104 N50e3c1998503444f8ef6f0e5ce5ee94c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Humans
106 rdf:type schema:DefinedTerm
107 N577e7a7ac3474933ad3f8c1948bbb08e schema:name Department of Melanoma, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
108 Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy
109 rdf:type schema:Organization
110 N57da5c63e254435380412475edb24103 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Protein Kinase Inhibitors
112 rdf:type schema:DefinedTerm
113 N58b8f5473b1b46d7acade1fefb31bf70 schema:name Department of Melanoma, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
114 rdf:type schema:Organization
115 N5f7f9abb5f554ac59205f3cf6a1630ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Skin Neoplasms
117 rdf:type schema:DefinedTerm
118 N77bc44fcf15745b3b8281eaf9441d65a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Mutation
120 rdf:type schema:DefinedTerm
121 N7df099595dfc4fd29c8b106b1dddd524 schema:name readcube_id
122 schema:value f07112b630ccbc8849e70d61f30549f232a39d0f39bea2a6d188eeb81cd943d6
123 rdf:type schema:PropertyValue
124 N872955d698244b039a55cbaf49c2cdb7 schema:name doi
125 schema:value 10.1186/1479-5876-10-85
126 rdf:type schema:PropertyValue
127 N8b7a8d8518cc4020bb91178a296d8db3 schema:name Hopital de la Timone, and Aix-Marseille Univ, 264 Rue St Pierre, 13885, Marseille CEDEX 05, Marseille, France
128 rdf:type schema:Organization
129 N8cda85457140462780bbbc91054f5709 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N980490647fd14ca184e76d016415b6a6 rdf:first sg:person.01021072757.16
132 rdf:rest N2fd7156708124e188fa457d461c36f1e
133 N9bced16c05e8420c8d2ce9f7d065c3a5 schema:name dimensions_id
134 schema:value pub.1050474099
135 rdf:type schema:PropertyValue
136 Nb13199026a51402eb626ebc500f520b1 schema:name Department of Melanoma, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
137 rdf:type schema:Organization
138 Nb1c5174e4eb64e258868e087b8f79f70 schema:name nlm_unique_id
139 schema:value 101190741
140 rdf:type schema:PropertyValue
141 Nb6b79d9287e946699126bb20c322d977 rdf:first sg:person.01061427172.10
142 rdf:rest Nf2f2710d12734af486ccb7f3062c4dc9
143 Nc8af633f52cd4a3ca7448b1697ab0442 rdf:first sg:person.01212502023.44
144 rdf:rest Nd2d0aeda35204a06bb001b5081cb9117
145 Nd1e590f202ea4057bb2e55c762081712 schema:volumeNumber 10
146 rdf:type schema:PublicationVolume
147 Nd2d0aeda35204a06bb001b5081cb9117 rdf:first sg:person.01274445211.76
148 rdf:rest N2a483edf3c8149118e3a725429c2e0a5
149 Nd4fc24a386004ebaa52690c0ed277021 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Melanoma
151 rdf:type schema:DefinedTerm
152 Ne4996f74913141e9b3331c9a90faa75a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Disease Progression
154 rdf:type schema:DefinedTerm
155 Nf2f2710d12734af486ccb7f3062c4dc9 rdf:first sg:person.0762206722.62
156 rdf:rest N980490647fd14ca184e76d016415b6a6
157 Nf80340e4846348cfbef693e0281b5e6a rdf:first sg:person.0762462504.03
158 rdf:rest Nb6b79d9287e946699126bb20c322d977
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
163 schema:name Oncology and Carcinogenesis
164 rdf:type schema:DefinedTerm
165 sg:grant.2440219 http://pending.schema.org/fundedItem sg:pub.10.1186/1479-5876-10-85
166 rdf:type schema:MonetaryGrant
167 sg:grant.4055141 http://pending.schema.org/fundedItem sg:pub.10.1186/1479-5876-10-85
168 rdf:type schema:MonetaryGrant
169 sg:journal.1032886 schema:issn 1479-5876
170 schema:name Journal of Translational Medicine
171 rdf:type schema:Periodical
172 sg:person.01021072757.16 schema:affiliation https://www.grid.ac/institutes/grid.15667.33
173 schema:familyName Testori
174 schema:givenName Alessandro
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021072757.16
176 rdf:type schema:Person
177 sg:person.01061427172.10 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
178 schema:familyName Maio
179 schema:givenName Michele
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10
181 rdf:type schema:Person
182 sg:person.01127536021.40 schema:affiliation N18ea12d2af514bc9a61a58d48aeafa7b
183 schema:familyName Simeone
184 schema:givenName Ester
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127536021.40
186 rdf:type schema:Person
187 sg:person.011671114717.29 schema:affiliation N8b7a8d8518cc4020bb91178a296d8db3
188 schema:familyName Grob
189 schema:givenName Jean-Jacques
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011671114717.29
191 rdf:type schema:Person
192 sg:person.01212502023.44 schema:affiliation N577e7a7ac3474933ad3f8c1948bbb08e
193 schema:familyName Ascierto
194 schema:givenName Paolo A
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
196 rdf:type schema:Person
197 sg:person.01274445211.76 schema:affiliation https://www.grid.ac/institutes/grid.478063.e
198 schema:familyName Kirkwood
199 schema:givenName John M
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274445211.76
201 rdf:type schema:Person
202 sg:person.014223631617.46 schema:affiliation https://www.grid.ac/institutes/grid.420086.8
203 schema:familyName Marincola
204 schema:givenName Francesco M
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014223631617.46
206 rdf:type schema:Person
207 sg:person.0752035543.31 schema:affiliation Nb13199026a51402eb626ebc500f520b1
208 schema:familyName Mozzillo
209 schema:givenName Nicola
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752035543.31
211 rdf:type schema:Person
212 sg:person.0762206722.62 schema:affiliation https://www.grid.ac/institutes/grid.5326.2
213 schema:familyName Palmieri
214 schema:givenName Giuseppe
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762206722.62
216 rdf:type schema:Person
217 sg:person.0762462504.03 schema:affiliation N58b8f5473b1b46d7acade1fefb31bf70
218 schema:familyName Grimaldi
219 schema:givenName Antonio M
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762462504.03
221 rdf:type schema:Person
222 sg:pub.10.1007/s00401-011-0887-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1045069601
223 https://doi.org/10.1007/s00401-011-0887-y
224 rdf:type schema:CreativeWork
225 sg:pub.10.1007/s00401-011-0933-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042903875
226 https://doi.org/10.1007/s00401-011-0933-9
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
229 https://doi.org/10.1038/nature00766
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/nature08314 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011492298
232 https://doi.org/10.1038/nature08314
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/nature08833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009288742
235 https://doi.org/10.1038/nature08833
236 rdf:type schema:CreativeWork
237 sg:pub.10.1038/nature08902 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006916541
238 https://doi.org/10.1038/nature08902
239 rdf:type schema:CreativeWork
240 sg:pub.10.1038/nature09454 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032620847
241 https://doi.org/10.1038/nature09454
242 rdf:type schema:CreativeWork
243 sg:pub.10.1038/nrclinonc.2011.69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041614560
244 https://doi.org/10.1038/nrclinonc.2011.69
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/nrm1498 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050758604
247 https://doi.org/10.1038/nrm1498
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/onc.2011.160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025711571
250 https://doi.org/10.1038/onc.2011.160
251 rdf:type schema:CreativeWork
252 sg:pub.10.1186/1479-5876-8-67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009398527
253 https://doi.org/10.1186/1479-5876-8-67
254 rdf:type schema:CreativeWork
255 https://app.dimensions.ai/details/publication/pub.1074805946 schema:CreativeWork
256 https://app.dimensions.ai/details/publication/pub.1081992405 schema:CreativeWork
257 https://doi.org/10.1002/0471142905.hg1011s57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021035685
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/j.ccr.2010.11.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006637390
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/j.cell.2009.12.040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028106155
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/j.ejca.2011.06.052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032185335
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.molcel.2005.10.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037007117
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/j.nbt.2012.02.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018116551
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejmoa050092 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007050226
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1056/nejmoa1002011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012824919
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1056/nejmoa1103782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041864150
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1056/nejmoa1104621 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036355137
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1056/nejmoa1112302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051449373
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1073/pnas.0900780106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018281397
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1093/carcin/bgp337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018188968
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1111/j.1755-148x.2010.00685.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017083437
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1128/mcb.00569-09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036424072
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1128/mcb.15.11.6430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050578408
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1128/mcb.26.6.2262-2272.2006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009784412
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1158/0008-5472.can-04-1443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014291431
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1158/0008-5472.can-05-1683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047572422
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1200/jco.2004.12.149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001105110
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1200/jco.2007.15.7636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034168619
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1200/jco.2010.28.15_suppl.8503 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083944529
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1200/jco.2010.32.4327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027360666
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1200/jco.2011.29.15_suppl.8502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083948941
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1200/jco.2011.29.15_suppl.8508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083948947
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1200/jco.2011.29.15_suppl.8519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083948957
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1200/jco.2011.29.15_suppl.8548 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083948984
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1200/jco.2011.38.2895 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014032151
314 rdf:type schema:CreativeWork
315 https://www.grid.ac/institutes/grid.15667.33 schema:alternateName European Institute of Oncology
316 schema:name Melanoma and muscle-cutaneous sarcomas Division, Istituto Europeo di Oncologia, Milan, Italy
317 rdf:type schema:Organization
318 https://www.grid.ac/institutes/grid.411477.0 schema:alternateName Azienda Ospedaliera Universitaria Senese
319 schema:name Medical Oncology and Immunotherapy, Department. of Oncology, University Hospital of of Siena, Istituto Toscano Tumori, Siena, Italy
320 rdf:type schema:Organization
321 https://www.grid.ac/institutes/grid.420086.8 schema:alternateName National Institute of Arthritis and Musculoskeletal and Skin Diseases
322 schema:name Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, MD, USA
323 rdf:type schema:Organization
324 https://www.grid.ac/institutes/grid.478063.e schema:alternateName University of Pittsburgh Cancer Institute
325 schema:name Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
326 rdf:type schema:Organization
327 https://www.grid.ac/institutes/grid.5326.2 schema:alternateName National Research Council
328 schema:name Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy
329 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...